Thus, it was suggested that in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K/Akt signaling, combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach [372]. This evidence concerns the gene PIK3CD and neoplasm.